JAK2 and neoplasm: The heterodimeric IFNGR1/IFNGR2 receptor complex on tumor cells binds to IFN-γ released by tumor-specific T lymphocytes, activating JAK1 and JAK2, which subsequently phosphorylate a transcription factor known as STAT1.